Educational Areas/Call for Grants
| Areas of Educational Interest | Available Funding | Call for Grants |
|---|---|---|
| Cardiovascular | ||
| Acute Coronary Syndrome |  |
|
| Coagulation Therapy | |
|
| High Risk Prior Myocardial Infarction |  |
|
| Hypertriglyceridemia |   |
|
| Heart Failure – SGLT2 Inhibition | |
|
| Secondary Prevention Acute Ischemic Stroke | |
|
| Endocrinology/Metabolic | ||
| Type 1 Diabetes | |
|
| Type 2 Diabetes | |
|
| Type 2 Diabetes – Heart Failure | |
|
| Type 2 Diabetes – Chronic Kidney Disease | |
|
| INFECTIONS & VACCINES | ||
| SARS-CoV-2 Monoclonal Antibodies | |
|
| SARS-CoV-2 Vaccine | |
|
| Nephrology | ||
| Chronic Kidney Disease - Anemia | |
|
| Chronic Kidney Disease – SGLT2 Inhibition | |
|
| Hyperkalemia | |
|
| Oncology | ||
| Advanced Breast Cancer | ||
| BRCA | |
|
| Non-BRCA | |
|
| DNA Damage Response | |
|
| PARP Inhibition | |
|
| HER2+ | |
CGA_ONC_HER2_Breast_2101_Pathology |
| Metastatic HR+ | |
|
| Cervical Cancer | ||
| Locally Advanced Cervical Cancer (LACC) | |
|
| Gastric Cancer | ||
| Gastric Cancer - HER2+ | |
|
| Hematology | ||
| CLL (Chronic Lymphocytic Leukemia) | |
|
| MCL (Mantle Cell Lymphoma) | |
|
| HCL (Hairy Cell Leukemia) | |
|
| WM (Waldenstrom Macroglobulinemia) | |
|
| Immuno-Oncology | ||
| Bladder Cancer | |
|
| Cervical Cancer | |
|
| imAE Management | |
|
| Extensive-Stage SCLC | |
|
| Non-Metastatic NSCLC | |
|
| iHCC (intermediate stage Hepatocellular Carcinoma) | |
|
| uHCC (unresectable Hepatocellular Carcinoma) | |
|
| Biliary Track Cancer (BTC) | |
|
| IO Diagnostics - Multidisciplinary Team | |
|
| IO Lung Diagnostics - Staging | |
|
| Neurofibromatosis | ||
| Neurofibromatosis Type 1 | |
|
| Plexiform Neurofibromas | |
|
| Non-Small Cell Lung Cancer | ||
| EGFR Diagnostics & Plasma Testing | |
|
| EGFRm+ NSCLC | |
|
| HER2+ NSCLC | |
|
| Ovarian Cancer | ||
| BRCA | |
|
| Non-BRCA | |
|
| PARP Inhibition | |
|
| DNA Damage Response | |
|
| Pancreatic Cancer | ||
| BRCA | |
|
| DNA Damage Response | |
|
| PARP Inhibition | |
|
| Prostate Cancer (mCRPC) | ||
| DNA Damage Response | |
|
| Homologus Recombination Repair | |
|
| PARP Inhibition | |
|
| Respiratory | ||
| Asthma (EX-US only) | |
|
| Chronic Cough (EX-US only) | |
|
| COPD | |
CGA Respiratory COPD Grand Rounds 2021 02 CGA Respiratory COPD Small Programs 2021 03
|
| CRSwNP (limited budget) | |
|
| Eosinophilic Esophagitis (limited budget) | |
|
| Severe Asthma |
|
|
| Rheumatology/Immunology/Autoimmune | ||
| Systemic Lupus Erythematosus (limited budget) |
|
|
| R & D Discovery | ||
| Scientific or educational activities designed to educate research scientists, principal researchers, drug development professionals, academics, pre-doctoral students, doctoral students and fellows. These programs must be educational and non-promotional in nature and planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities. | |
|